PDCD1 and Fatigable weakness: A report indicates that 6 of 7 patients with MG treated with PD‐1/CTLA‐4 inhibitors developed these complications [5], a pattern sometimes referred to as the ‘triple‐M complication’ (myasthenia, myositis, and myocarditis), which is known for its high mortality and rapid progression.